Mainz Biomed (MYNZ) CFO details stock option grants and vesting

Rhea-AI Filing Summary

Mainz Biomed N.V. Chief Financial Officer William J. Caragol filed an initial ownership report as of 01/01/2026. He reports beneficial ownership of 0 Ordinary Shares directly.

The filing lists several employee stock options to buy Ordinary Shares held directly. These include an option for 70,000 shares at an exercise price of $4.95, with 50% vested on 03/04/2025 and the remainder vesting 25% on 03/24/2026 and 25% on 03/04/2027. Additional options cover 3,899 shares at $200 (fully vested), 2,000 shares at $497.6, 1,000 shares at $302.8, and 1,000 shares at $191.2, each with four-year vesting schedules as described in the footnotes.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Caragol William J

(Last) (First) (Middle)

MAINZ BIOMED N.V.

ROBERT KOCH STRASSE 50

(Street)

MAINZ 2M 55129

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
01/01/2026

3. Issuer Name and Ticker or Trading Symbol
MAINZ BIOMED N.V. [ MYNZ ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares	0	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Buy)	03/04/2025	(1)	Ordinary Shares	70,000	$4.95	D
Employee Stock Option (Right to Buy)	11/04/2021	(2)	Ordinary Shares	3,899	$200	D
Employee Stock Option (Right to Buy)	04/29/2022	(3)	Ordinary Shares	2,000	$497.6	D
Employee Stock Option (Right to Buy)	12/21/2022	(4)	Ordinary Shares	1,000	$302.8	D
Employee Stock Option (Right to Buy)	06/30/2023	(5)	Ordinary Shares	1,000	$191.2	D

Explanation of Responses:

1. 50% of the option vested upon grant on 03/04/2025; the remaining balance vests 25% on 03/24/26 and 25% on 03/04/2027.

2. Fully vested.

3. Four-year vesting schedule: 25% vests on 04/29/2023, and the remainder vests 1/36 per month until 4/29/2026.

4. Four-year vesting schedule: 25% vests on 12/21/2023, and the remainder vests 1/36 per month until 12/21/2026.

5. Four-year vesting schedule: 25% vests on 06/30/2024, and the remainder vests 1/36 per month until 6/30/2076.

	/s/ William Caragol	01/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What does the Form 3 filed for MYNZ disclose about insider ownership?

The Form 3 shows that Chief Financial Officer William J. Caragol directly owns 0 Ordinary Shares of Mainz Biomed N.V. as of 01/01/2026, but holds several employee stock options for Ordinary Shares.

How many Mainz Biomed (MYNZ) shares can the CFO acquire through stock options?

The filing lists employee stock options on 70,000 Ordinary Shares at an exercise price of $4.95, plus additional options on 3,899, 2,000, 1,000, and 1,000 Ordinary Shares at exercise prices of $200, $497.6, $302.8, and $191.2, respectively.

What is the vesting schedule for the MYNZ CFO’s 70,000-share option?

For the 70,000-share option granted on 03/04/2025, 50% vested upon grant, with the remaining balance vesting 25% on 03/24/2026 and 25% on 03/04/2027.

Which Mainz Biomed (MYNZ) stock options are already fully vested for the CFO?

The option covering 3,899 Ordinary Shares at an exercise price of $200, granted on 11/04/2021, is described as fully vested.

How do the four-year vesting schedules work for the MYNZ CFO’s other options?

For the options granted on 04/29/2022, 12/21/2022, and 06/30/2023, 25% vests on the one-year anniversary of each grant date and the remainder vests at 1/36 per month until the respective end dates stated in the footnotes.

Does the MYNZ CFO hold his Mainz Biomed securities directly or indirectly?

The Form 3 shows all listed Ordinary Shares and employee stock options as held with direct ownership, with no indirect ownership entities disclosed in the excerpt.